Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer

GlaxoSmithKline117 enrolled

Overview

This study will examine specific biomarkers in primary invasive breast cancer and explore their correlation with patient outcome following standard neoadjuvant treatment.

Study Type

OBSERVATIONAL

Enrollment

117

Conditions

Neoplasms, Breast

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * The patient has 18 years of age or older at the time of consent. * The patient has provided pre-treatment tumor samples for WT1 expression screening and gene expression profiling in the context of the NCT01220128 study. * The patient has a histologically or cytologically confirmed primary invasive breast cancer. * The patient has provided written informed consent before any new information or new material is provided to the Sponsor. * The patient is planned to receive, is receiving or has received standard and/or investigational therapy for breast cancer. * The patient is planned to receive, is receiving or has received standard and/or investigational therapy for breast cancer. Exclusion Criteria: Not applicable.

Locations (29)

Outcomes

Primary Outcomes

The presence of a specific predictive gene expression signature in tumor tissues

Time frame: At randomization and at definitive surgery which may be up to 30 weeks post randomization.

The presence of immune infiltration in tumor tissues

Time frame: At randomization and at definitive surgery which may be up to 30 weeks post randomization.

The presence of other candidate biomarkers in tumor tissues

Time frame: At randomization and at definitive surgery which may be up to 30 weeks post randomization.

The pathological response (complete response or partial response) in the breast.

Time frame: At definitive surgery which may be up to 30 weeks post randomization.

Disease free interval

Time frame: Time from definitive surgery to the date of first recurrence of the disease up to maximally 6 years.

Disease free survival

Time frame: Time from definitive surgery to either the date of first recurrence of the disease or the date of death (whatever the cause), whichever occurs first, up to maximally 6 years.

Overall survival

Time frame: Time from definitive surgery to the date of death, irrespective of the cause of death. Patients still alive will be censored at the date of the last contact up to maximally 6 years.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.